In vivo gene transfer to sites of inflammatory disease provides a novel method both for studying the effects of cytokines and growth factors, and for therapeutic intervention. Macrophages play a pivotal role in the development and control of inflammation and are therefore logical cells to use for genetic modification and in vivo gene delivery. In this study we show that macrophages (both cell lines and primary cultures) can be transfected by recombinant adenoviruses expressing ␤-galactosidase, that the macrophages become activated by the transfection process as determined by generation of nitric oxide and can be easily manipulated
Introduction
Gene transfer could provide a highly effective form of therapy for inflammatory and autoimmune conditions because short-term expression of biologically active transgenes could re-orientate the immune response and thus permanently alter the course of the disease, especially if the genes were delivered to the inflamed site by a cell type normally involved in the disease. Genetically modified macrophages are ideal vehicles for this approach due to their ability to localise to sites of injury and involvement in many aspects of the inflammatory process. 1, 2 Macrophages are part of the innate immune system and form an important link between innate and adaptive immunity. They are capable of a range of functions depending on their microenvironment. They localise to sites of inflammation following chemotactic signals, adhere to the endothelium utilising selectins, integrins and their appropriate counter-receptors and then transmigrate to the focus of injury. 3 Although responsible for injury in models of inflammation, macrophages are also crucial to resolution of injury and for tissue re-modeling and repair. The processes that control these events are increasingly being understood: (1) macrophage infiltration is required for appropriate wound repair; [4] [5] [6] (2) macrophage uptake of apoptotic infiltrating neutrophils, lymphocytes and eosinophils is important in resolution of pulmonary inflammation in animal models 7, 8 and human disease; 9, 10 to localise to inflamed glomeruli after direct injection into the renal artery of rats with an experimentally induced glomerular inflammation caused by nephrotoxic nephritis. The injection of transfected macrophages reduces the severity of injury in this model of glomerulonephritis as shown by a reduction in the degree of albuminuria. This approach provides a favourable system for gene delivery in inflammatory disease and shows that both the functional properties of the transfected macrophage as well the transgene it is engineered to produce are relevant for in vivo gene transfer. Gene Therapy (2000) 7, 263-270.
increase severity of peritoneal inflammation; 11 and (4) macrophage removal of lymphocytes is involved in the resolution of viral infections. 12 Thus, far from contributing to tissue injury appropriately transfected macrophages delivered to sites of inflammation could promote tissue repair. Whether this is feasible will depend on the influences of transfection, the transgene they express and the interaction of the transfected macrophages with the local milieu. We and others have been analysing the factors that enable macrophages to develop anti-inflammatory properties and describe here an efficient system that demonstrates that transfected macrophages are able to attenuate injury in vivo, in a model of immunemediated glomerulonephritis.
Gene transfer into macrophages can be attained via a number of methods including polylysinated mannose, 13 HIV-based vectors 14 and recombinant adenoviruses. [15] [16] [17] Recombinant adenoviruses are the most efficient vector, however, the effect of transfection on the functional characteristics of macrophages has not been extensively studied, with the present published work emphasising that adenoviral transfection does not alter the properties or development of macrophages. 18, 19 The telescoped model of nephrotoxic glomerulonephritis (NTN) is a macrophage-dependent model of acute inflammation that provides a suitable in vivo system for assessing the effectiveness of gene transfer using modified macrophages. It is induced by injection of rabbit anti-rat glomerular basement (GBM) antibodies into rats that have been immunised against rabbit IgG, and results in injury characterised by infiltration of the glomerulus with macrophages, the development of capillary thrombi, cellular crescents and subsequently glomerulosclerosis. 20 The rats with NTN develop substantial proteinuria and subsequently reduced glomerular filtration rate, analogous to patients with rapidly progressive glomerulonephritis. Therefore, NTN provides a valuable model to study the influence of gene therapy on macrophagedependent acute glomerular inflammation.
The results show first that macrophage cell lines and primary cultures can be efficiently transfected by recombinant adenovirus to express a transgene and that genetically modified macrophages localise preferentially to the site of glomerular inflammation. Second, both the environment in which transfection occurs and the vector used alter macrophage properties and that these properties can be utilised to favour their localisation to inflamed glomeruli. Third, that transfer of genetically modified macrophages reduced the severity of injury in this model of glomerulonephritis, even though injury is macrophage dependent. This demonstrates the potential of using transfected macrophages to investigate and eventually treat inflammatory disease.
Results

Transfection of macrophages by recombinant adenoviruses
The efficiency of adenoviral gene transfer on both rat bone marrow-derived macrophages (BMDM) and the rat alveolar macrophage cell line, NR8383, was assessed using a recombinant adenovirus expressing ␤-galactosidase gene (Av1Bng). X-gal assay 2-14 days after transfection of NR8383 showed Ͼ95% of the cells transfected with viral doses from 10 to 100 plaque forming units (p.f.u.) per cell ( Figure 1a) . The bone marrow-derived cells transfected 5-7 days after isolation showed between 50 and 80% of the cells transfected (Figure 1b) . The transfected macrophages were larger than non-transfected macrophages and had processes extending from the surface similar to those seen in activated macrophages. Thus, adenovirus efficiently transfects primary macrophage cultures, but the transfection alters the morphology.
Activation of macrophages by adenoviral transfection
The change in the phenotypic characteristics of the macrophages following adenoviral transfection was assessed by monitoring their capacity to make nitric oxide (NO). Nitric oxide generation was assessed by measuring the level of nitrite in the medium 48 h after transfection. The influence of three different recombinant adenoviruses were tested to distinguish between the effect of the adenovirus itself from that of the bacterial transgene: Av1Bng containing the ␤-galactosidase gene, Ad dl327 the recombinant adenovirus from which Av1Bng was derived and retained the E1A region of the adenoviral genome and Ad dl312 which is a standard replication deficient adenovirus containing no insert. 21 Transfection with all three viruses into NR8383 cells at a dose of 60 p.f.u. per cell resulted in a small increase in the level of nitrite production compared with control cells (Figure 2a) . However, even macrophages transfected with low doses of virus generated greatly increased amounts of NO when stimulated with LPS ( Figure 2a) . Similar results were obtained with bone marrow-derived macrophages which showed a progressive increase in NO production with increasing viral dose as well as an augmented response to LPS (Figure 2b) . Overall, bone marrow-derived macrophages were capable of generating greater amounts of NO than NR8383 cells thus explaining the greater absolute levels observed but the pattern of changes was identical in the two groups. Thus transfection with replication deficient adenovirus has similar effects on macrophage NO generation as natural infection with live viruses: high doses of virus activate macrophages whereas lower doses prime them in a way reminiscent of interferon-␥ (IFN-␥). 22 We have previously shown that pre-incubation with IL-4 blocks IFN-␥-induced priming of bone marrowderived macrophages for NO generation, 22 and so we assessed the effect of incubation of macrophages with IL-4 before transfection. IL-4 had no effect on the efficiency of transfection or amount of ␤-galactosidase produced (data not shown) but inhibited the effect of transfection on NO generation both by NR8383 cells and bone marrow-derived macrophages. The initial NO production by NR8383 cells following adenoviral transfection was completely prevented by incubating the macrophages with IL-4 starting 24 h before transfection (Figure 2a) , and the subsequent increase in nitrite production in response to LPS was also markedly attenuated ( Figure 2a ). IL-4 had a similar effect on rat bone marrow-derived macrophages both in response to adenovirus transfection and after LPS stimulation.
In vivo gene delivery in nephrotoxic nephritis using transfected macrophages
Having demonstrated the efficiency of adenoviral transfection, we next assessed the effectiveness of transfected macrophages as gene transfer vectors in nephrotoxic nephritis (NTN) a macrophage-dependent model of acute glomerular inflammation. First, we quantified localisation of injected macrophages to the inflamed kidney by injecting fluorescently labelled NR8383 cells into the renal artery. These experiments showed that considerable numbers of labelled macrophages localised to glomeruli ( Figure 1c ). We then injected between 4 and 6 × 10 6 NR8383 cells transfected 48 h before with Av1Bng directly into the left renal artery either 6 h after the induction of disease or in non-diseased rats. Glomeruli isolated from the injected kidney 24 h later contained large numbers of transfected macrophages as assessed using an Xgal assay, whereas the contralateral kidney contained no transfected cells (Figure 1d and e). Transfected bone marrow-derived macrophages localised to the inflamed glomeruli with even greater efficiency following injection into the renal artery ( Figure 1f ). Transfected macrophages could not be detected in the liver, spleen or lung after injection into the renal artery.
The efficiency with which the injected macrophages localised to the kidney was assessed by determining both the proportion of glomeruli containing transfected macrophages and the number of transfected cells within each glomerulus. The effect of incubation with LPS before injection was also assessed to ascertain whether activation of the macrophages in vitro increased their ability to adhere to inflamed glomeruli. Twenty-four hours after injection with LPS activated ␤-galactosidase expressing macrophages 82.6 ± 11.4% of the glomeruli contained transfected macrophages with an average of 2.7 ± 0.6 macrophages per glomerulus when cells activated with LPS were injected into rats with nephrotoxic nephritis. Macrophages not activated in vitro localised less well to Time-course of macrophage residence and effect of macrophage transfer on the severity of injury in NTN Injury in the autologous phase of nephrotoxic nephritis is macrophage dependent whereas in other settings macrophages can contribute to the resolution of injury, therefore it was important to assess both the duration of glomerular residence of the transfected macrophages' gene transfer and their effect on the severity of injury. The percentage of glomeruli containing transfected macrophages started at 82 ± 11.4% and then declined to 44 ± 8.2% at day 2, 35 ± 13.6% by day 3 and 9 ± 4.1% by day 4 (Figure 4) .
Albuminuria is the most accurate method to assess the severity of glomerular injury in this model and normally it increases progressively over the first 4 days studied in the absence of interventions. All the nephritic rats developed marked albuminuria compared with normal controls. Albuminuria was less severe in the injected animals from day 2 onwards and this difference was statistically significant at day 4 after injection of macrophages (Figure 5a ). The reduction of albuminuria in the rats injected with transfected macrophages was not a result of decreased glomerular filtration as the injected animals also had a decline in the urine albumin to urinary creatinine ratio, which corrects for differences in glomerular filtration rate. Histological assessment of the total number of cells (both inflammatory and non-inflammatory and resident and infiltrating cells) per glomerular area showed no difference between injected rats and control rats and in addition there was no difference in cells numbers between the injected kidney and the contralateral kidney (data not shown). This implies that any reduction in injury in the injected rats was not due to reduced cellular infiltration but secondary to altered function of the cells present, as is the case when rats with NTN are treated systemically with anti-inflammatory cytokines.
23,24
Figure 4 The time-course of macrophage gene transfer. Assessed by counting percentage of glomeruli containing transfected macrophage days 1-4 after injection of transfected NR8383 cells into rats with nephrotoxic nephritis. There is a decrease in the number of glomeruli containing transfected macrophages over the time-course from 82% on day 1 to 9% by day 4 (results expressed as mean ± s.d.).
Figure 5 Assessment of degree of albuminuria and renal function after gene transfer in NTN. (a) Comparison of the degree of albuminuria in rats with nephrotoxic nephritis between those animals that received renal artery injection of transfected macrophages and control animals which were not injected. The degree of albuminuria was less at each time-point for the animals receiving transfected macrophages compared with disease controls after day 2. This difference was statistically significant by day 4. (b) The urine protein to creatinine ratio in the same animals as in (a), which shows that the reduction in albuminuria was genuine and not a result of reduced glomerular filtration. (*P Ͻ 0.05) (results expressed as mean ± s.e.m., n = at least three at each time-point).
Gene Therapy
Discussion
Macrophages infiltrate damaged tissues and have a critical role in many disease states especially in infections, autoimmune inflammation and malignancy. 25, 26 Developing gene transfer approaches to modify their functions will have wide applications both as a vehicle for delivery of individual cytokines and as a method for infiltrating damaged tissue with cells programmed to perform a particular function. The system described here demonstrates the feasibility of using the host's own macrophages as vehicles to deliver genes because it results in transfection rates of more than 95% the rat alveolar macrophage cell line NR8383, and 60% transfection for rat bone marrow-derived macrophages. Transfection with adenovirus alters macrophage function, as might be expected from the macrophage response to other viral infections; 27-29 these results with recombinant adenovirus demonstrate such activation also with replication-deficient virus. We have demonstrated that adenoviral transfection activates and primes macrophages to respond to pro-inflammatory stimuli with increased nitric oxide generation and that this activation can be down-regulated by IL-4. Thus both the vector and conditions of transfection are important in controlling the phenotype of the macrophage.
The transfection of macrophages by recombinant adenoviruses in vivo may be of importance for gene transfer experiments or trials. The activation of macrophages in the absence of viral replication may contribute to the initial inflammation and subsequent immune response produced by these vectors in vivo [30] [31] [32] [33] which limit the effectiveness of gene transfer. In addition, the macrophage has evolved to eliminate virally infected cells while they remain resistant to being killed by infectious viruses. Worgall et al 34 demonstrated that macrophages appeared to be important in the initial elimination of adenoviral genome from the lungs of mice transfected with a ␤-galactosidase expressing adenovirus and are probably important in the development of subsequent immune response to both the adenovirus and the transgene. 35 This process has also been shown to be inhibited by reducing TNF-␣ activity, a cytokine principally produced by macrophages, using a specific TNF binding protein. 33 Furthermore, our results also show the degree that transfection induced macrophage activation is influenced by cytokines. Thus, incubation with particular cytokines can be used to give the cells distinct phenotypic properties both to enhance their localisation at the designated site but also alter their functional behaviour to be beneficial to the modulation of disease.
These principles are demonstrated by results of studies with transfected macrophages delivered directly into the renal artery. The efficiency of localisation was increased by the presence of glomerular inflammation and by stimulating the macrophages with LPS before administration. In nephritic rats injected with LPS-stimulated transfected macrophages twice as many glomeruli were transfected compared with normal animals injected with macrophages that had not been stimulated with LPS. The difference in efficiency is emphasized by the observation that glomeruli contained almost three times as many transfected macrophages. This highlights the importance of the interaction between the activity of the infused cells and the microenvironment of the inflamed site and that both endothelial and macrophage activation are required for efficient localisation. The increase in the number of macrophages is significant compared with the resident population as at day 1 of disease there are about 10-20 macrophages per glomeruli so the transfected population are around 15-30% of the total number of macrophages. Transfection itself with adenovirus did not appear to alter the ability of macrophages to localise to inflamed glomeruli as efficiency was similar to non-transfected labelled macrophages.
Our approach represents an efficient method for introducing genes into the glomerulus which hitherto has proved a difficult target for gene therapy with few of the conventional nonviral or viral methods proving successful, perhaps because of the kidneys' natural defences against occlusion of the glomerular circulation by particulate matter. The Sendai virus method developed by Imai and coworkers 36 was able to transfect around 15-30% of the glomeruli with a plasmid expressing ␤-galactosidase and was also able to transfect the glomerulus with cDNA for transforming growth factor-␤ (TGF-␤) and platelet-derived growth factor (PDGF) with biological effect. 37 Heikkila et al 38 transfected glomeruli in pigs with recombinant adenovirus with high efficiency using chilled isolated perfusion of a single kidney, however, in general, adenoviruses do not transfect the glomeruli in rats even following cold perfusion or viral modification. [39] [40] [41] [42] Kitamura has used retroviral transfected mesangial cells 43 and macrophages 44 to act as delivery vehicles to the glomerulus but in the case of the macrophages the length of expression has not been analysed nor the influence on the severity of a disease model. Recently, in mice bone marrow macrophages transfected to express human glucocerebrosidase also localised to glomeruli in LPS-treated mice. 45 Thus our approach represents a useful novel method for gene transfer in inflammatory renal disease with distinct functional effects.
At first sight it is surprising that delivery of an inert gene to inflamed glomeruli should result in a reduction in injury as assessed by albuminuria. Normally in NTN the level of albuminuria increases over the first 4 days and remains elevated. A number of possible mechanisms may be involved for the reduction seen in our experiments. The adenoviral transfection and/or LPS stimulation could give the macrophages properties to reduce injury such as increased interleukin-10 synthesis 18 or increased NO generation reducing the number of inflammatory leucocytes. 46 Some support for the potential anti-inflammatory properties of recombinant adenoviruses comes from a recent study where injection of adenovirus expressing ␤-galactosidase into arthritic joints reduced the severity of inflammation. 47 Other possible mechanisms may be that the infusion of the transfected macrophages may prevent infiltration of pathogenic macrophages by competition for adhesion sites, also the operation itself by stimulating endogenous steroids may reduce injury and our experiments do not distinguish between these. The fact that the reduction in albuminuria is greater than 50% at day 4 may imply that there is a systemic component to the mechanism for reduction in injury. 47 However, the important point is that adenovirus-transfected macrophages can be delivered to a site of inflammation without worsening injury.
The decline in the severity of injury in the rats treated with transfected macrophages is mirrored by the decrease in transfected macrophage numbers in the glomeruli, which is consistent with the hypothesis that macrophages traffic from the site of injury as inflammation resolves. 48 Equally it is possible that the cells die within the glomeruli by apoptosis.
In conclusion, adenoviral transfection of macrophages is an efficient approach enabling effective in vivo transgene delivery which raises a number of issues. Transfection can alter the properties of macrophages by virtue of the virus, the transgene contained and the local milieu in which transfection occurs. The macrophages once transfected can be manipulated to localise to an inflamed site with potentially beneficial consequences on injury. Therefore, adenovirus-transfected macrophages can be modified on a number of levels and should provide a valuable system in the study, and potentially treatment of inflammatory and autoimmune diseases.
Materials and methods
Cells and reagents NR8383 rat alveolar macrophage cell line, derived from outbred Sprague-Dawley rats (ATCC, Rockville, MD, USA) was grown in Ham's F12 medium (Gibco, Paisley, UK) supplemented with 10% fetal calf serum (FCS; Gibco), 100 U/ml penicillin and 100 g/ml streptomycin (full Hams F-12). Rat bone marrow-derived cells were isolated by aspiration of femur and tibia and suspended in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 20% L929 conditioned medium, 100 U/ml penicillin and 100 g/ml streptomycin (full DMEM) and plated on 15 cm tissue culture plates with 1 × 10 7 cells per plate. Macrophages were subsequently isolated by adherence. L929 conditioned medium was produced using a standard protocol. Rat IL-4 was produced as previously described 23 using a Chinese hamster ovary IL-4 cell line (a kind gift from Dr Neil Barclay, MRC Cellular Immunology Unit, Oxford University). All cells were incubated in a humidified incubator at 37°C with 5% CO 2 . Nephrotoxic serum was prepared as described previously. 49 Recombinant adenovirus Add1312 (a gift from Dr F Graham, McMaster University, Ontario) 21 and Addl327 (a gift from Gene Therapy, Novartis, Gaithersburg, MD, USA) were both null recombinant adenoviruses. Av1Bng (a gift from Gene Therapy, Novartis) contained the ␤-galactosidase gene under the control of a CMV promoter. All the recombinant viruses were grown in 293 cells as previously described 50 and purified by two rounds of caesium chloride ultracentrifugation followed by dialysis against 10 mm Tris pH 7.4, 1 mm MgCl 2 and 10% (v/v) glycerol at 4°C and storage at −70°C. The titre of virus was assessed by plaque assay on 293 cells and the absence of wild-type virus was confirmed by plaque assay on Hela cells. 50 Transfection of NR8383 cells and bone marrow-derived macrophages in vitro Before transfection NR8383 cells were grown for 48 h in full Hams F12 medium supplemented with 10% L929 conditioned medium as a source of M-CSF. They were harvested from tissue culture plate using a cell scraper, centrifuged at 170 g for 5 min, washed in Hams F-12 and the cell pellet resuspended in Hams F-12 supplemented with 2% fetal calf serum. Recombinant adenovirus (Addl 312, Addl327 or Av1Bng) was added and the cells incubated at 37°C with 5% CO 2 for 90 min with rocking every 15 min, then full medium added. Rat bone marrowderived macrophages were grown for 5-6 days before transfection in 5 ml of DMEM with 2% FCS containing recombinant adenovirus. The cells were incubated at 37°C/5% CO 2 for 90 min with rocking every 15 min after which the medium was replaced with full DMEM. Expression of ␤-galactosidase was examined in NR8383 cells and bone marrow-derived macrophages using 5-bromo-4-chloro-3-indolyl ␤-d-galactopyranoside (X-gal) assay. 51 Fluorescent labelling of macrophages NR8383 cells were harvested and the cell pellet incubated with 4 m PKH-26GL (Sigma, Poole, Dorset) for 5 min, which fluorescently labels the cell membrane without altering the cells properties. The cells were washed in Hams F-12 three times to remove unbound PKH-26GL and then rested in full Hams F-12 for 24 h before injection.
Assessment of macrophage activity following transfection
The effect of transfection on generation of NO by NR8383 cells and bone-derived macrophages was assessed by nitrite production, assayed using a Greiss reaction. In brief, 48 h after transfection 200 l aliquots of medium from the cells were removed and incubated with 50 l of Greiss reagent (0.5% sulphanilamide, 0.05% N-(lnaphthyl) ethylendiamine dihydrochloride in 2.5% phosphoric acid) in 96-well flat-bottomed cultures for 10 min. The optical densities of the assay samples were then measured at 540 nm using a solution of phenol red free DMEM. The cells were stimulated with lipopolysaccharide (LPS; Sigma) (40 ng/ml) for a further 24 h and nitrite production again measured. In certain experiments the cells were incubated with IL-4 for 24 h before transfection and continued in the medium thereafter.
Nephrotoxic nephritis
The telescoped model of nephrotoxic nephritis was induced using a standard protocol. 23 In brief, male Sprague-Dawley rats (purchased from Harlan, Bicester, UK) weight 190-250 g were preimmunised with 1 mg rabbit IgG (Sigma) subcutaneously followed 1 week later by injection of 5 ml/kg of rabbit serum containing high titres of anti-rat glomerular basement membrane antibodies. Renal function was assessed by measuring urine creatinine using picric acid colormetric assay (Sigma) and albuminuria measured using rocket immunoelectrophoresis. 49 In vivo transfer of modified macrophages To enable delivery of genetically modified macrophages to the left kidney the rats were anaesthetised using hypnorm (Jannsen, High Wycombe, UK) IM (0.3 ml/kg) and diazepam (Phoenix Pharmaceuticals, Gloucester, UK) IP (2.5 mg/kg) 6 h after the induction of nephrotoxic nephritis. The left renal artery was exposed using a standard anterior approach and then directly cannulated using a 27-G needle. Between 4 and 6 × 10 6 transfected macroGene Therapy phages were injected in a volume of 0.4 ml over 1 min and bleeding stopped by compression of renal artery for 5 min. Adequate perfusion of the left kidney was seen before closure of the abdominal wall. Animals were killed between 1 and 4 days after operation or induction of disease. In certain experiments fluorescently labelled macrophages were injected into the rats' left renal artery using an identical technique.
Pathology
To assess the efficiency of transfection, glomeruli were isolated from the kidney using sieving through 250 m and 150 m diameter sieves with collection on a 65 m sieve. The glomeruli were fixed with 2% paraformaldehyde in sodium phosphate buffer at 4°C for 2 h, then washed in phosphate-buffered saline before staining in X-gal solution with 0.002% deoxycholic acid and 0.001% tergitol. The number of glomeruli transfected was assessed by counting 150-200 randomly selected glomeruli and the numbers of cells per transfected glomeruli measured. To visualise fluorescently labelled macrophages fresh renal tissue was snap-frozen in isopentane embedded in OCT. Five micrometre sections were incubated with anti-rabbit IgG-FITC (Sigma) to outline the glomerular basement membrane before viewing under a fluorescent microscope.
